GSK GLP-1 Tanzeum OK'd in US; Now what?
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won FDA approval on 15 April for its subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist Tanzeum (albiglutide) as a once-weekly adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, which affects about 24 million people in the US, accounting for more than 90% of the nation's diabetes population.